Overview

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.
Phase:
Phase 4
Details
Lead Sponsor:
Zhengzhou University
Treatments:
Apatinib